米食品医薬品局(FDA)が、抗PD-1抗体ペムブロリズマブについて、化学療法施行中あるいは施行後に病勢進行を認めた進行子宮頸がんに対して適応拡大【FDA】

FDA approves pembrolizumab for advanced cervical cancer with disease progression during or after chemotherapy


On June 12, 2018, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck and Co. Inc.) for patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.

 

 

コメント

Leave a comment

Your email address will not be published.


*